A Living Tissue Bank of Patient-Derived Organoids From Glioma Tumors

To establish primary patient-derived three-dimensional organoid cultures from low grade and high-grade gliomas to study the mechanisms that contribute to i.e.

resistance to radiotherapy and/or chemotherapy and immunotherapy, dedifferentiation, tumor invasion among others, in primary and recurrent tumors.

Primary Objectives:

• Establishment of primary patient-derived organoids (PDO) of 'de novo' and recurrent high-grade glioma (HGG) and low-grade glioma (LGG)
• Phenotypic, genetic, epigenetic and transcriptomic characterization of HGG and LGG organoids and resemblance to the parental tumor (i.e. characterization of specific cell populations and genomic and transcriptomic profiles of PDOs)
• Investigation of combinations of new or standard glioma systemic treatments (i.e immunotherapy, chemotherapy) with or without radiation (i.e. protons, photons).

Secondary objectives

• Establishment of co-cultures of HGG and LGG organoids with immune cells.
• Investigation of radiation-triggered cell death mechanisms on PDOs after irradiation with photons and protons.
• Investigation of dedifferentiation mechanisms of LGG to HGG in the context of radiation w/wo immunotherapy.

Inclusion criteria

• MRI diagnosis of low grade glioma (LGG) or high grade glioma (HGG)
• Age 18 years or older
• Patient is eligible for a resection of the tumor

Exclusion criteria

• Contra-inidication for neurosurgical resection of the tumor.
• Incapacitated patient, unable to give informed consent.